

References for Joslin Diabetes Center & Joslin Clinic Clinical Guideline for Adults with Diabetes 5/21/10

Approach to Care

1. ADA: Standards of medical care in diabetes--2010. *Diabetes Care* 2010; 33 Suppl 1:S11-61
2. Mensing C, Lasichak A, Boucher J, Lamb B, et al National Standards for Diabetes Self-Management Education. *Diabetes Care* 2006; 29 (Suppl 1):S78-S85.
3. Deakin T, McShane CE, Cade JE, Williams RD. Group based training for self-management strategies in people with type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2005;18;(2):CD003417.
4. Renders CM, Valk GD, Griffin SJ et al. Interventions to improve the management of diabetes in primary care, outpatient and community settings: a systematic review. *Diabetes Care* 2001; 1821-1833.

A1C

1. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care* 2009; 32(7):1327-1334.
2. Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. *Diabetes Care* 2010; 33(3):562-568.
3. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. *Diabetes Care* 2008; 31(8):1473-1478.
5. ADA: Standards of medical care in diabetes--2010. *Diabetes Care* 2010; 33 (Suppl 1):S11-61.

Glucose Monitoring

1. Hirsch IB, Bode BW, Childs BP et al. Self-Monitoring of Blood Glucose (SMBG) in insulin- and non-insulin-using adults with diabetes: consensus recommendations for improving SMBG accuracy, utilization, and research. *Diabetes Technol Ther* 2008; 10:419-439.
2. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1C. *JAMA* 2006 295:1688-1697.
3. Welschen LM, Bloemendal E, Nijpels G et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. *Diabetes Care* 2005; 28:1510-1517.
4. ADA: Standards of medical care in diabetes--2010. *Diabetes Care* 2010; 33 (Suppl 1):S11-61.
5. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. *N Engl J Med* 2008; 359:1464-1476.

Hypoglycemia

1. Cryer PE, Davis SN, Shamon H. Hypoglycemia in Diabetes. *Diabetes Care* 2003; 26:1902-12.

2. Cox DJ, Kovatchev BP, Koev D. et al. Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus. *Int J Behav Med* 2004; 11:212-8.
3. Brackenridge A, Wallbank H, Lawrenson RA, Russell-Jones D. Emergency management of diabetes and hypoglycemia. *Emerg Med J* 2006; 23:183-5.
4. Heller, SR. Minimizing hypoglycemia while maintaining glycemic control. *Diabetes* 2008; 57: 3177-3183.
5. Cryer, PE Hypoglycemia: still the limiting factor in the glycemic management of diabetes. *Endocrine Practice* 2008; 14:750-756.
6. ADA: Standards of medical care in diabetes--2010. *Diabetes Care* 2010; 33 (Suppl 1):S11-61.

Diabetes Self-Management Education (DSME) and Medical Nutrition Therapy (MNT)

1. ADA: Standards of medical care in diabetes--2010. *Diabetes Care* 2010; 33 (Suppl 1):S11-61.
2. Funnell MM, Brown TL, Childs BP et al. National standards for diabetes self-management education. *Diabetes Care* 2007; 30:1630-1637.
3. Franz MJ, Monk A, Barry B, McClain K, Weaver T, Cooper N, Upham P, Bergenstal R, Mazze RS. Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized controlled clinical trial. *J Am Diet Assoc* 1995; 95:1009-1017.
4. Lemon CC, Lacey K, Lohse B, Hubacher DO, Klawitter B, Palta M. Outcomes monitoring of health, behavior, and quality of life after nutrition intervention in adults with type 2 diabetes. *J Am Diet Assoc* 2004; 104:1085-15.
5. Miller CK, Edwards L, Kissling G, Sanville L. Nutrition education improves metabolic outcomes among older adults with diabetes mellitus: results from a randomized controlled trial. *Prev Med* 2002; 34:252-9.

Physical Activity

1. Physical Activity and Public Health: Updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc* 2007; 39: 1423-1434.
2. Physical Activity and Public Health in Older Adults: Update Recommendation from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc* 2007; 39:1435-1445.
3. ACSM Position Stand on Exercise and Type 2 Diabetes. *Med Sci Sports Exerc* 2000; 32:1345-1360.

Cardiovascular Health

1. ADA: Standards of medical care in diabetes--2010. *Diabetes Care* 2010; 33 (Suppl 1):S11-61.
2. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. *Circulation* 2000; 102:1014-1019.
3. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008; 358:580-591.
4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. *JAMA* 2004; 291:335-342.

5. Smith SC, Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. *Circulation* 2006; 113:2363-2372.
6. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. *Diabetes Care* 2009; 32:187-192.
7. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 2009; 360:129-139.
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008; 359:1577-1589.
9. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005; 353:2643-2653.

Aspirin

1. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* 2009; 373:1849-1860.
2. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. *BMJ* 2008; 337:a1840.
3. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. *BMJ* 2009; 339:b4531.
4. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. *Diabetes Care* 2010; 33:1395-1402.

Stress testing

1. Lawrence H. Young; Frans J. Th. Wackers; Deborah A. Chyun; Janice A. Davey; Eugene J. Barrett; Raymond Taillefer; Gary V. Heller; Ami E. Iskandrian; Steven D. Wittlin; Neil Filipchuk; Robert E. Ratner; Silvio E. Inzucchi; for the DIAD Investigators Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes: The DIAD Study: A randomized controlled trial. *JAMA* 2009; 301:1547-1555.
2. Bax, J., Young, L., Frye, R., Bonow, R., Steinberg, H., Barrett, E. Screening for coronary artery disease in patients with diabetes. *Diabetes Care* 2007; 30:2729-2736.
3. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL Jr. ACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing) 2002. American College of Cardiology Web site. Available at: [www.acc.org/clinical/guidelines/exercise/ dirIndex.htm](http://www.acc.org/clinical/guidelines/exercise/dirIndex.htm).

4. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, Guerci AD, Lima JA, Rader DJ, Rubin GD, Shaw LJ, Wiegers SE: Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. *Circulation* 2006; 114:1761–1791.

Lipids

1. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 2004; 110:227-239.
2. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008; 371:117-125.
3. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004; 364:685-696.
4. Ganda OP. Refining lipoprotein assessment in diabetes: apolipoprotein B makes sense. *Endocr Pract* 2009; 15:370-376.
5. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* 2010; 362:1563-74.
6. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. *Am J Cardiol* 2006; 98:1363-1368.
7. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. *Expert Rev Cardiovasc Ther* 2008; 6:391-409.
8. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. *Mayo Clin Proc* 2008; 83:470-478.
9. Davidson MH. The use of colesvelam hydrochloride in the treatment of dyslipidemia: a review. *Expert Opin Pharmacother* 2007; 8:2569-2578.
10. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008; 359:2195-2207.
11. Ganda, OP. Dyslipidemia: Pathogenesis and Management. In Principles of Diabetes Mellitus, 2nd Edition, L. Poretzky, ed., Springer, New York. 2010: 435-456.

Blood Pressure

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993; 16:434-444.
2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998; 317:703-713.
3. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. *Lancet* 2000; 355:253-259.

4. Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. *Lancet* 2008; 37:1513-1518.
5. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ et al. Projected effect of dietary salt reductions on future cardiovascular disease. *N Engl J Med* 2010; 362:590-599.
6. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iamathi E, Kostis JB et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med* 2005; 165:1401-1409.
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ* 2009; 338:b1665.
8. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. *N Engl J Med* 2008; 359:1565-1576.

Renal

1. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. *Lancet* 2000; 355:253-259.
2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998; 317:703-713.
3. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. *JAMA* 2003; 290:2159-2167.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med* 1993; 329:1456-1462.
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001; 345:861-869.
6. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 2001; 345:870-878.
7. ADA: Standards of medical care in diabetes--2010. *Diabetes Care* 2010; 33 (Suppl 1):S11-61.

Eyes

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; 352:837-853.
2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998; 317:703-713.
3. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. *N Engl J Med* 2000; 342:1376.
4. Early Treatment Diabetic Retinopathy Study Report Number 1: Photocoagulation for diabetic macular edema. *Arch Ophthalmol* 103:1796-1806, 1985.

5. Early Treatment Diabetic Retinopathy Study Report Number 9: Early photocoagulation for diabetic retinopathy. *Ophthalmology* 98:766-785, 1991.
6. Early Treatment Diabetic Retinopathy Study Report Number 10: Grading diabetic retinopathy from stereoscopic color fundus photographs-An extension of the modified Airlie House Classification. *Ophthalmology* 98:786-806, 1991.
7. The Diabetic Retinopathy Clinical Research Network Writing Committee. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2010; in press.
8. Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. *Lancet* 2008; 372: 1394-1402.
9. Sjolie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. *Lancet* 2008; 372:1385-1393.
10. Mohamed, Q. Management of diabetic retinopathy: a systematic review. *JAMA* 2007; 298: 902-916.

Peripheral Neuropathy

1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R et al. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care* 2005; 28:956-962 .
2. Freeman R. Autonomic peripheral neuropathy. *Lancet* 2005; 365:1259-1270.
3. ADA: Standards of medical care in diabetes--2010. *Diabetes Care* 2010; 33 (Suppl 1):S11-61.

Feet

1. ADA: Standards of medical care in diabetes--2010. *Diabetes Care* 2010; 33 (Suppl 1):S11-61.
2. Valk GD, Kriegsman DM, Assendelft WJ. Patient education for preventing diabetic foot ulceration. *Cochrane Database Syst Rev.* 2005 Jan 25;(1):CD001488.
3. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. *JAMA* 2005 293:217-228.

Mental Health

Adherence

1. Anderson BJ, Vangsness L, Connell A, Butler D, Goebel-Fabbri A, Laffel LM. Family conflict, adherence, and glycemic control in youth with short duration type 1 diabetes. *Diabet Med* 19:635-642, 2002.
2. Odegard PS, Capoccia K: Medication taking and diabetes: a systematic review of the literature. *Diabetes Educ* 2007; 33:1014-1029.
3. Skovlund SE, Peyrot M. The Diabetes Attitudes, Wishes, and Needs (DAWN) program: A new approach to improving outcomes of diabetes care. *Diabetes Spectrum* 18:136-142, 2005.

Anxiety

1. Grigsby AB. Prevalence of anxiety in adults with diabetes. *J Psychosom Res* 53:1053-1060, 2002.

Depression

1. Anderson R, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes. *Diabetes Care* 2001; 24:1069-1078.
2. De Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. *Psychosom Med* 2001; 63:619-630.
3. Gonzalez JS, Safre SA, Cagliero E, Wexler DJ, Delahanty L, Wittenberg E, Blais MA, Meigs JB, Grant RW. Depression, self-care, and medication adherence in type 2 diabetes. *Diabetes Care* 2007; 30:2222-2227.
4. Grey M, Whittemore R, Tamborlane W. Depression in type 1 diabetes in children: natural history and correlates. *J Psychosom Res* 2002 ; 53: 907-911.
5. Lustman PJ, Anderson RJ, Freeland KE, deGroot M, Carney RM, Clouse RE: Depression and poor glycemic control: a meta-analytic review of the literature. *Diabetes Care* 2000; 23:934-942.
6. Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? *Diabetes Care* 2000; 23:1556-1562.

Eating Disorders

1. Goebel-Fabbri AE, Fikkan J, Franko DL, Pearson K, Anderson BJ, Weinger K. Insulin restriction and associated morbidity and mortality in women with type 1 diabetes. *Diabetes Care* 2008; 31:415-419.

Immunizations

1. Smith S, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. *Diabetes Care* 2000; 23:95-108.
2. ADA: Standards of medical care in diabetes--2010. *Diabetes Care* 2010; 33 (Suppl 1):S11-61.

Women's Health

1. Holing EV. Preconception care of women with diabetes: the unrevealed obstacles. *J Matern Fetal Med* 2000; 9:10-13.
2. Schwartz AV, Sellmeyer DE. Women, type 2 diabetes, and fracture risk. *Curr Diab Rep* 2004; 4:364-369.
3. Enzlin P et al. Sexual dysfunction in women with type 1 diabetes. *Diabetes Care* 2002; 25:672-677.
4. Nicodimus KK, Folsom AR. Type 1 and type 2 diabetes and incidence of hip fracture in postmenopausal women. *Diabetes Care* 2001; 24:1192-1197.
5. Holmberg AH, Nilsson PM, Nilsson JA, Akesson K. The association between hyperglycemia and fracture risk in middle age. A prospective, population-based study of 22,444 men and 10,902 women. *J Clin Endocrinol Metab* 2008; 93:815-822.

Men's Health

1. Lue TF. Erectile dysfunction. *N Engl J Med* 2000; 342:1802-1813.
2. Beckman TJ, Abu-Lebdeh HS, Mynderse LA. Evaluation and medical management of erectile dysfunction. *Mayo Clin Proceedings* 2006; 81: 385-390.
3. Nehra, A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. *Mayo Clin Proceedings* 2009; 84:139-148.

Dental Care

1. Simpson TC, Needleman IG, Wild SH, Moles DR, Mills EJ. Treatment of periodontal disease for glycaemic control in people with diabetes. *Cochrane Database Syst Rev* 2010; 5: CD004714.
2. Bahekar AA et al. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. *Am Heart J* 2007; 154:830-837.
3. Humphrey LL et al. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. *J Gen Intern Med* 2008; 12:2079-2086.